Evidence map›Paper›PMID 28612106›Full record

ArticleDiabetologia2017

The kynurenine:tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease.

Eirik W Rebnord, Elin Strand, Øivind Midttun, Gard F T Svingen, Monika H E Christensen, Per M Ueland, Gunnar Mellgren, Pål R Njølstad, Grethe S Tell, Ottar K Nygård and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Tryptophan Indole Derivatives: Key Players in Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. The role of the kynurenine pathway in cardiovascular disease.Frontiers in cardiovascular medicine · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Eirik W RebnordDepartment of Clinical Science, University of Bergen, Bergen, Norway. Eirik.Rebnord@gmail.com.
Elin StrandDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Øivind MidttunBevital, Bergen, Norway.
Gard F T SvingenDepartment of Heart Disease, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
Monika H E ChristensenDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Per M UelandDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Gunnar MellgrenDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Pål R NjølstadDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Grethe S TellDepartment of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Ottar K NygårdDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Eva R PedersenKG Jebsen Centre for Diabetes Research, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NOUniversity of Bergen · NOBevital (Norway) · NO

Funding

Norwegian Health Association and the Norwegian Extra Foundation for Health and Rehabilitation through EXTRA funds Grant number: 2014/FOM5642
6 · The paper itself

Abstract

aims/hypothesisThe tryptophan metabolite kynurenine has potent immune modulatory and vasoactive properties. Experimental data implicate kynurenine in obesity-related morbidities. Epidemiological studies are, however, sparse. We evaluated associations of the plasma and urine kynurenine:tryptophan ratio (KTR) to incident type 2 diabetes.

methodsWe followed 2519 individuals with coronary artery disease (CAD; 73.1% men) without diabetes at baseline for a median of 7.6 years, during which 173 (6.9%) new incidences of type 2 diabetes were identified. Multivariate Cox regression analyses were applied to investigate the prospective relationships of plasma and urine KTR with new onset type 2 diabetes.

resultsAt inclusion, mean (SD) age was 61.3 (10.4) years, BMI was 25.9 (3.71) kg/m CONCLUSIONS/

interpretationUrine KTR is a strong predictor of incident type 2 diabetes in individuals with CAD. Potential clinical implications and possible pathogenic roles of renal kynurenine excretion in type 2 diabetes development should be further elucidated.

Indexed as

AgedCoronary Artery DiseaseDiabetes Mellitus, Type 2FemaleHumansKynurenineMaleMiddle AgedMultivariate AnalysisProspective StudiesRisk FactorsTryptophanKynurenineTryptophanAmino acid metabolismBiomarkersClinical epidemiologyType 2 diabetes

Identifiers

PMID28612106
PMCPMC5552838
OpenAlexW2626636841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.